IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 428,376 shares, an increase of 46.3% from the November 30th total of 292,751 shares. Based on an average trading volume of 707,283 shares, the short-interest ratio is currently 0.6 days. Approximately 0.6% of the company’s stock are sold short. Approximately 0.6% of the company’s stock are sold short. Based on an average trading volume of 707,283 shares, the short-interest ratio is currently 0.6 days.
IGC Pharma Trading Down 1.4%
IGC Pharma stock traded down $0.00 during mid-day trading on Monday, hitting $0.30. 325,402 shares of the company’s stock were exchanged, compared to its average volume of 1,136,955. The business has a 50 day moving average price of $0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.89 and a current ratio of 1.32. IGC Pharma has a 1-year low of $0.25 and a 1-year high of $0.50. The firm has a market capitalization of $27.45 million, a PE ratio of -4.22 and a beta of 0.24.
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $0.19 million during the quarter. IGC Pharma had a negative net margin of 583.91% and a negative return on equity of 96.54%.
About IGC Pharma
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps.
Read More
- Five stocks we like better than IGC Pharma
- Do not delete, read immediately
- How the Rich Retire
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- How Long Will $1M Last in Retirement?
- [No Brainer Gold Play]: “Show me a better investment.”
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
